FIGURE SUMMARY
Title

Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases

Authors
Sahin, C., Magomedova, L., Ferreira, T.A.M., Liu, J., Tiefenbach, J., Alves, P.S., Queiroz, F.J.G., Oliveira, A.S., Bhattacharyya, M., Grouleff, J., Nogueira, P.C.N., Silveira, E.R., Moreira, D.C., Leite, J.R.S.A., Brand, G.D., Uehling, D., Poda, G., Krause, H., Cummins, C.L., Romeiro, L.A.S.
Source
Full text @ J. Med. Chem.
Fig. 1

Figure 1. Chemical structures of fibrates, thiazolidinediones (TZDs), and glitazars.

Fig. 2

Figure 2. Similarity of chemical structures of stearic acid and saturated anacardic acid.

Fig. 3

Figure 3. Saturated derivatives (3?23) designed from the mixtures of anacardic acids (1) and cardanols (2).

Fig. 4

Figure 4. In vitro screening of CNSL derivatives for PPAR?, PPAR?, and PPAR? activity reveals a subset of selective pan-activators. HEK293 cells were transiently co-transfected with GAL4-hPPAR? (A), GAL4-hPPAR? (B), or GAL4-hPPAR? (C) together with UAS-luciferase reporter and treated with positive controls (10 nM GW7647, 100 nM Rosi, and 10 nM GW0742) or 50 ?M of indicated compounds for 16 h. Data represent mean ± standard deviation (SD) (N = 3). RLU, relative luciferase units = luciferase light units/?-galactosidase × time. Vehicle (DMSO) response was set to 1. C10:0, decanoic acid; C14:0, myristic acid; C18:0, stearic acid; C18:1n9, oleic acid. *P < 0.05 relative to corresponding vehicle, using one-way analysis of variance (ANOVA) with Holm??idák correction.

Fig. 5

Figure 5. CNSL derivatives activate PPAR? target genes in primary hepatocytes in a gene-selective manner. Primary hepatocytes were isolated from wild-type (WT) mice and incubated with vehicle (Veh, DMSO), 50 ?M CNSL derivatives or 10 ?M of positive controls: WY14643 (WY, PPAR? agonist), GW7647 (GW, PPAR? agonist), muraglitazar (Mura, PPAR?/? agonist), rosiglitazone (Rosi, PPAR? agonist) for 16 h. Expression of fatty acid uptake genes Fabp1 (A) and Cd36 (B), and fatty acid oxidation genes, Fgf21 (C) and Pdk4 (D) were analyzed by quantitative polymerase chain reaction (QPCR). Veh mRNA expression was set to 1. Data represent mean ± SD (N = 3). *P < 0.05 vs Veh using one-way ANOVA with Holm??idák correction.

Fig. 6

Figure 6. CNSL derivatives differentially regulate the expression of PPAR? target genes and adipocyte differentiation in 3T3-L1 cells. 3T3-L1 fibroblasts were differentiated for 11 days in the presence of vehicle (DMSO), 25 ?M of indicated CNSL derivatives or 10 ?M rosiglitazone (Rosi). Cells were harvested for Oil Red O staining and mRNA on day 11. (A) Cells were imaged under 10× magnification (n = 2/per group). (B) Lipid accumulation was quantitated by spectrophotometric analysis of extracted Oil Red O. mRNA expression was analyzed by QPCR for two key regulators of adipogenesis, (C) Ppar? and (D) Cebp?; fatty acid uptake genes (E) aP2 (Fabp4), (F) Lpl, and (G) Cd36; adipose-specific adipokine gene (H) AdipoQ and glucose uptake gene (I) Glut4. Vehicle mRNA expression was set to 1 and Rosi value was set to 100%. Data represent mean ± SD (N = 3). *P < 0.05 vs vehicle and #P < 0.05 vs Rosi; using one-way ANOVA with Holm??idák correction.

Fig. 7

Figure 7. In vivo testing of CNSL derivatives using transgenic zebrafish that express human PPAR?, PPAR?, or PPAR? reveal tissue-specific activation. Activation of human PPAR in the zebrafish embryo results in GFP expression. Basal activity of PPAR?, PPAR?, and PPAR? is observed with vehicle (DMSO) treatment and is strongly increased in the presence of the full agonist for each receptor. Positive controls are WY (WY14643) for PPAR?, Rosi (rosiglitazone) for PPAR?, and GW (GW0742) for PPAR?, respectively. Compounds were screened at their respective EC50?s determined from their dose?response curves in HEK293 cells with a few exceptions: 4 was screened at 1.5 ?M for all receptors because of toxicity at higher concentrations; for PPAR?, 20 and 27 were screened below their EC50?s due to toxicity at higher concentrations. Each image depicts a representative embryo. Note that embryos incubated with 27 were imaged using a different microscope.

Fig. 8

Figure 8. Thermostabilization of hPPAR?-LBD, hPPAR?-LBD, and hPPAR?-LBD by carboxylic acid-containing CNSL derivatives. Thermal shift assays of hPPAR?-LBD (A) interacting with 25 ?M GW7647 or 25 ?M CNSL derivatives. Stabilization of the hPPAR?-LBD (B) and the hPPAR?-LBD (C) by 50 ?M Rosi (rosiglitazone), 50 ?M CAY (CAY10592), or 50 ?M CNSL derivatives, respectively. The temperature?response curves were analyzed using the four-parameter dose?response curve function in GraphPad Prism 8 and Tm values were determined. ?Tm values were calculated for each compound relative to DMSO and are listed in the legend. Data points represent mean ± standard error of the mean (SEM) (N = 3).

Fig. 9

Figure 9. In vivo pharmacokinetic profile of 23 (LDT409) in C57BL/6 mice. The plasma concentration of 23 (LDT409) in mice after (A) a single intraperitoneal injection (IP) at 40 mg/kg and (B) oral administration in peanut butter treat at 100 mg/kg. Data represent mean ± SEM (N = 4 per time point).

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Med. Chem.
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.